Journal article
The brain-derived neurotrophic factor Val66Met polymorphism predicts response to exposure therapy in posttraumatic stress disorder
KL Felmingham, C Dobson-Stone, PR Schofield, GJ Quirk, RA Bryant
Biological Psychiatry | ELSEVIER SCIENCE INC | Published : 2013
Abstract
Background: The most effective treatment for posttraumatic stress disorder (PTSD) is exposure therapy, which aims to facilitate extinction of conditioned fear. Recent evidence suggests that brain-derived neurotrophic factor (BDNF) facilitates extinction learning. This study assessed whether the Met-66 allele of BDNF, which results in lower activity-dependent secretion, predicts poor response to exposure therapy in PTSD. Methods: Fifty-five patients with PTSD underwent an 8-week exposure-based cognitive behavior therapy program and provided mouth swabs or saliva to extract genomic DNA to determine their BDNF Val66Met genotype (30 patients with the Val/Val BDNF allele, 25 patients with the Met..
View full abstractGrants
Awarded by National Institute of Mental Health
Funding Acknowledgements
This work was supported by a National Health Medical Research Council Program Grant (400403) to RAB, a National Health Medical Research Council Enabling grant (No. 480184) to PRS, and a University of New South Wales Vice-Chancellors Post-doctoral Fellowship to CD-S. We thank Kerrie Pierce for DNA sample preparation.RAB, KLF, CD-S, and PRS report holding grants from the National Health and Medical Research Council and Australian Research Council. PRS reports paid speaker fees from Janssen unrelated to this study and GJQ report no biomedical financial interests or potential conflicts of interest.